Acute Coronary Syndrome market size in the 7MM was around ~USD 2,670 million in 2023 and is expected to increase with a significant CAGR during the study period (2020-2034).

Acute Coronary Syndrome Treatment Market Size, Companies

Acute Coronary Syndrome  Market Infographic

1. Key Insights
2. Report Introduction
3. Executive Summary
4. Acute Coronary Syndrome Market Overview at a Glance
4.1. Market Share Distribution by Therapies (%) in 2020 in the 7MM
4.2. Market Share Distribution by Therapies (%) in 2034 in the 7MM
5. Epidemiology and Market Forecast Methodology
6. Key Events
7. Disease Background and Overview
7.1. Introduction
7.2. Sign and Symptoms
7.3. Risk Factors
7.4. Pathogenesis
7.5. Classification of ACS
7.6. Biomarkers
7.7. Diagnosis
7.7.1. Differential Diagnosis
8. Treatment and Management
8.1. Treatment and Management Guidelines
8.1.1. AHA/ACC/HFSA Guidelines for the Management of Heart Failure: Executive Summary: 2022
8.1.2. NICE Guidelines for Acute coronary syndromes: 2020
8.1.3. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation: 2017
8.1.4. ESC Guidelines for the Management of Acute Coronary Syndromes (ACS): 2023
8.1.5. ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
8.1.6. Guideline Adherence and Longterm Clinical Outcomes in Patients with AMI in Japan
9. Epidemiology and Patient Population of ACS in the 7MM
9.1. Key Findings
9.2. Assumptions and Rationale
9.3. Total Incident Cases of ACS in the 7MM
9.4. The United States
9.4.1. Total Incident Cases of ACS in the United States
9.4.2. Type-specific Incident Cases of ACS in the United States
9.4.3. Type-specific Incident Cases of AMI in the United States
9.4.4. Gender-specific Incident Cases of ACS in the United States
9.5. EU4 and the UK
9.5.1. Total Incident Cases of ACS in EU4 and the UK
9.5.2. Type-specific Incident Cases of ACS in EU4 and the UK
9.5.3. Type-specific Incident Cases of AMI in EU4 and the UK
9.5.4. Gender-specific Incident Cases of ACS in EU4 and the UK
9.6. Japan
9.6.1. Total Incident Cases of ACS in Japan
9.6.2. Type-specific Incident Cases of ACS in Japan
9.6.3. Type-specific Incident Cases of AMI in Japan
9.6.4. Gender-specific Incident Cases of ACS in Japan
10. Patient Journey
11. Marketed Drugs
11.1. Key Cross Competition
11.2. LODOCO (colchicine): AGEPHA Pharma
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Safety and Efficacy
11.3. TNKase (tenecteplase): Genentech
11.3.1. Product Description
11.3.2. Regulatory Milestones
11.3.3. Safety and Efficacy
11.4. REPATHA (evolocumab): Amgen
11.4.1. Product Description
11.4.2. Regulatory Milestones
11.4.3. Other Developmental Activities
11.4.4. Safety and Efficacy
11.5. ZONTIVITY (vorapaxar): Merck
11.5.1. Product Description
11.5.2. Regulatory Milestones
11.5.3. Other Developmental Activity
11.5.4. Safety and Efficacy
11.6. PRALUENT (alirocumab): Regeneron and Sanofi
11.6.1. Product Description
11.6.2. Regulatory Milestones
11.6.3. Other Developmental Activities
11.6.4. Safety and Efficacy
12. Other Marketed Assets
12.1. Key Cross Competition
12.2. INSPRA (eplerenone): Pfizer
12.2.1. Product description
12.2.2. Regulatory milestones
12.2.3. Safety and efficacy
12.3. PLAVIX (clopidogrel bisulfate): Sanofi-Aventis/Bristol-Myers Squibb
12.3.1. Product description
12.3.2. Regulatory milestones
12.3.3. Other developmental activities
12.3.4. Safety and efficacy
12.4. BRILINTA/BRILIQUE (ticagrelor): AstraZeneca
12.4.1. Product description
12.4.2. Regulatory milestones
12.4.3. Safety and efficacy
12.5. EFFIENT/EFIENT (prasugrel): Daiichi Sankyo/Eli Lilly and Company
12.5.1. Product description
12.5.2. Regulatory milestones
12.5.3. Other development activity
12.5.4. Safety and efficacy
12.6. ATACAND (candesartan): AstraZeneca/Takeda
12.6.1. Product description
12.6.2. Regulatory milestones
12.7. DIOVAN (valsartan): Novartis
12.7.1. Product description
12.7.2. Regulatory milestones
12.7.3. Safety and efficacy
13. Emerging Therapies
13.1. Key Cross Competition
13.2. Selatogrel (ACT-246475): Idorsia Pharmaceuticals and Viatris
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.2.5. Analyst View
13.3. Dutogliptin: Recardio
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Safety and Efficacy
13.3.5. Analyst View
13.4. FARXIGA/FORXIGA (dapagliflozin): AstraZeneca
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Safety and efficacy
13.4.5. Analyst View
13.5. FDY-5301: Faraday Pharmaceuticals
13.5.1. Product Description
13.5.2. Other Developmental Activity
13.5.3. Clinical Development
13.5.4. Safety and Efficacy
13.5.5. Analyst View
13.6. Dalcetrapib (RO4607381): DalCor Pharmaceuticals and Roche
13.6.1. Product Description
13.6.2. Other Developmental Activities
13.6.3. Clinical Development
13.6.4. Safety and Efficacy
13.6.5. Analyst View
13.7. Vicagrel: Jiangsu Vcare PharmaTech
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Analyst View
13.8. Zalunfiban (RUC 4): CeleCor Therapeutics
13.8.1. Product Description
13.8.2. Other Developmental Activities
13.8.3. Clinical Development
13.8.4. Safety and Efficacy
13.8.5. Analyst View
13.9. Ziltivekimab: Novo Nordisk
13.9.1. Product Description
13.9.2. Other Developmental Activities
13.9.3. Clinical Development
13.9.4. Analyst View
13.10. Milvexian: Bristol Myers Squibb and Johnson &amp; Johnson Innovative Medicine
13.10.1. Product Description
13.10.2. Other Developmental Activities
13.10.3. Clinical Development
13.10.4. Analyst View
13.11. ProtheraCytes: CellProthera and BioCardia
13.11.1. Product Description
13.11.2. Other Developmental Activities
13.11.3. Clinical Development
13.11.4. Safety and Efficacy
13.11.5. Analyst View
13.12. KAND567: Kancera
13.12.1. Product Description
13.12.2. Other Developmental Activities
13.12.3. Clinical Development
13.12.4. Safety and Efficacy
13.12.5. Analyst View
13.13. Olpasiran (AMG 890): Amgen and Arrowhead Pharmaceuticals
13.13.1. Product Description
13.13.2. Other Developmental Activities
13.13.3. Clinical Development
13.13.4. Safety and Efficacy
13.13.5. Analyst View
13.14. Orticumab: Abcentra
13.14.1. Product Description
13.14.2. Other Developmental Activities
13.14.3. Clinical Development
13.14.4. Analyst View
14. Acute Coronary Syndrome (ACS): 7MM Analysis
14.1. Key Findings
14.2. Market Outlook
14.3. Conjoint Analysis
14.4. Key Market Forecast Assumptions
14.5. Total Market Size of ACS in the 7MM
14.6. United States Market Size
14.6.1. Total Market Size of ACS in the United States
14.6.2. Market Size of ACS by Therapies in United States
14.7. EU4 and the UK Market Size
14.7.1. Total Market Size of ACS in EU4 and the UK
14.7.2. Market Size of ACS by Therapies in EU4 and the UK
14.8. Japan Market Size
14.8.1. Total Market Size of ACS in Japan
14.8.2. Market Size of ACS by Therapies in Japan
15. Unmet Needs
16. SWOT Analysis
17. KOL Views
18. Market Access and Reimbursement
18.1. United States
18.1.1. Centre for Medicare and Medicaid Services (CMS)
18.2. EU4 and the UK
18.2.1. Germany
18.2.2. France
18.2.3. Italy
18.2.4. Spain
18.2.5. United Kingdom
18.3. Japan
18.3.1. MHLW
18.4. Reimbursement Scenario and Key HTA Decisions in ACS
19. Appendix
19.1. Bibliography
19.2. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

DelveInsight’s "Acute Chronic Syndrome Market Insight, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of Acute Chronic Syndrome, historical and forecasted epidemiology as well as the Acute Chronic Syndrome therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Acute Coronary Syndrome Market

Acute Coronary Syndrome Market Insight, Epidemiology And Market Forecast - 2034

DelveInsight's Acute Coronary Syndrome Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Acute Coronary Syndrome market trends in 7MM.